Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 35Prostate Cancer Metastatic 3Neoplasm Metastasis 3Prostate CA 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Oligometastatic Prostate Cancer 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Cancer 1Intraprostatic Prostate Cancer 1Genital Diseases, Male 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Radiosurgery 2zimberelimab 1quemliclustat 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Oligometastatic Prostate Cancer × Androgen Antagonists × Clear all
NCT06972511 2025-05-15

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

RenJi Hospital

Phase 2/3 Recruiting
120 enrolled
Genitourinary

Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡